Lunit, a global leader in AI solutions for cancer diagnostics and therapeutics, has announced a new nonexclusive collaboration with Agilent Technologies Inc. (NYSE: A), a major player in life sciences, diagnostics, and applied chemical markets. Together, the two companies will work to develop AI-driven companion diagnostic solutions, combining Lunit’s advanced artificial intelligence capabilities with Agilent’s long-standing expertise in tissue-based companion diagnostics. The collaboration is designed to address the growing demand for innovative, precise biomarker assays that are critical in drug development.
Through this partnership, Lunit and Agilent aim to create cutting-edge AI-powered diagnostic tools that will enhance both diagnostic accuracy and the ability to assess therapeutic effectiveness. The initial phase of the collaboration will center on integrating Lunit’s proven AI algorithms with Agilent’s high-performance assays to evaluate biomarkers essential for advancing new pharmaceutical therapies.
The solutions that emerge from this joint effort will support pharmaceutical companies in the development of companion diagnostic (CDx) products, helping to improve precision in biomarker testing and ultimately expanding access to more personalized treatment options for patients. This collaboration underscores both companies’ shared commitment to accelerating the path toward precision medicine.
Brandon Suh, CEO of Lunit, emphasized the importance of the initiative, noting, “Biomarker testing is fundamental to precision oncology, but much of it still relies heavily on manual interpretation. By combining Agilent’s leadership in tissue-based diagnostics with Lunit’s validated AI algorithms, we can enable pharmaceutical partners to bring biomarker-driven therapies to market more quickly and confidently, ensuring that patients receive the right treatment at the right time.”
Nina Green, vice president and general manager of Agilent’s Clinical Diagnostics Division, added, “Agilent remains dedicated to providing state-of-the-art diagnostic solutions for our pharmaceutical partners and patients. Partnering with Lunit allows us to deliver the next generation of companion diagnostic tools that will advance precision medicine globally.”
Initially, the collaboration will concentrate on co-developing AI-based assays for both research and clinical trial applications. This agreement represents a pivotal step for both companies, reinforcing their commitment to redefining the role of artificial intelligence in precision oncology and translational medicine.
